Upadacitinib outdoes abatacept for rheumatoid arthritis
14 Dec 2020
byAudrey Abella
The oral selective Janus kinase (JAK) inhibitor upadacitinib was superior to IV abatacept, a T-cell costimulation modulator, for the treatment of rheumatoid arthritis (RA) that is refractory to biologic disease-modifying antirheumatic drugs (bDMARDs), the SELECT-CHOICE trial has shown.
